z-logo
open-access-imgOpen Access
Managing the Pharmaceutical Industry—Health System Interface
Author(s) -
Barbara J. Zarowitz,
Bruce K. Muma,
Peter Coggan,
Glenn M. Davis,
Gregory L. Barkley
Publication year - 2001
Publication title -
annals of pharmacotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.926
H-Index - 113
eISSN - 1542-6270
pISSN - 1060-0280
DOI - 10.1345/aph.10412
Subject(s) - vendor , pharmaceutical industry , marketing , the internet , medicine , pharmaceutical marketing , business , pharmacology , computer science , world wide web
BACKGROUND: Direct-to-consumer advertising, media, and Internet marketing to physicians and patients, as well as enticing marketing strategies, are used by the pharmaceutical industry to ensure market share growth of new drugs. Our health system adopted a strict vendor policy governing detailing and sampling activities of pharmaceutical representatives, but realized that further analysis of vendor influence in our system was needed.OBJECTIVE: An assessment of tangible benefits, ethical concerns, and financial liabilities and gains was conducted to reassess the need for further vendor restriction.CONCLUSIONS: Based on our findings, several recommendations have been made. Medical practices and health systems are encouraged to establish and enforce explicit vendor policies, measure their effectiveness, partner proactively with representatives to deliver a drug-detailing message consistent with system initiatives, monitor and regulate continuing medical education funding, and implement strategies to ensure appropriate drug use.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom